Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy

Seminars in Oncology

Volumn 29, Issue 6 SUPPL. 19, 2002, Pages 57-60

  Bardet, Etienne ^{a,b,c,d,e,f,g,h,i}   Martin, Laurent ^{a,b,c,d,e,f,g,h}   Calais, Gilles ^{a,b,c,d,e,f,g,h}   Tuchais, Claude ^{a,b,c,d,e,f,g,h}   Bourhis, Jean ^{a,b,c,d,e,f,g,h}   Rhein, Béatrix ^{a,b,c,d,e,f,g,h}   Feham, Nouredine ^{a,b,c,d,e,f,g,h}   Alphonsi, Marc ^{a,b,c,d,e,f,g,h}  

^a CRLCC Nantes Atlantique   (France)

^b Guillaume le Conquérant Center   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

^d CENTRE PAUL PAPIN   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f LIMOGES UNIVERSITY HOSPITAL   (France)

^g CHR   (France)

^h INSTITUT SAINTE CATHERINE   (France)

ⁱ Ctr Regl Lutte Contre Cancer N   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTIEMETIC AGENT; DEXAMETHASONE; ONDANSETRON; PILOCARPINE;

ACUTE TOXICITY; ALLERGIC REACTION; ASTHENIA; BLOOD PRESSURE MONITORING; CANCER CONTROL; CANCER PREVENTION; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; HEAD AND NECK CANCER; HUMAN; HYPOTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; NAUSEA; PAIN; PAROTID GLAND CANCER; PATIENT COMPLIANCE; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION FIELD; RANDOMIZED CONTROLLED TRIAL; RASH; SQUAMOUS CELL CARCINOMA; VOMITING; XEROSTOMIA;

AMIFOSTINE; CARCINOMA, SQUAMOUS CELL; CYTOPROTECTION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; XEROSTOMIA;

EID: 0036984990     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.37348     Document Type: Conference Paper

References (14)

1. Smoluk GD, Fahey RC, Calabro-Jones PM, et al: Radioprotection of cells in culture by WR-2721 and derivatives: Form of the drug responsible for protection. Cancer Res 48:3641-3647, 1988
2. Calabro-Jones PM, Aguilera JA, Ward JF, et al: Uptake of WR-2721 derivatives by cells in culture: Identification of the transported form of the drug. Cancer Res 48:3634-3640, 1988
3. Shaw LM, Turrisi AT, Glover DJ, et al: Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys 12:1501-1504, 1986
4. Shaw LM, Bonner H, Lieberman R: Pharmacokinetic profile of amifostine. Semin Oncol 23:18-22, 1996 (suppl 8)
5. Rasey JS, Krohn KA, Menard TW, et al: Comparative biodistribution and radioprotection studies with three radioprotective drugs in mouse tumors. Int J Radiat Oncol Biol Phys 12:1487-1490, 1986
6. Kligerman MM, Turrisi AT III, Urtasun RC, et al: Final report on phase I trial of WR-2721 before protracted fractionated radiation therapy. Int J Radiat Oncol Biol Phys 14:1119-1122, 1988
7. McDonald S, Meyerowitz C, Smudzin T, et al: Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys 29:747-754, 1994
8. Schonekas KG, Wagner W, Prott FJ: Amifostine: A radioprotector in locally advanced head and neck tumors. Strahlenther Onkol 175:27-29, 1999 (suppl 4)
9. Brizel DM, Wasserman TH, Henke M, et al: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18:3339-3345, 2000
10. Wasserman T, Mackowiak JI, Brizel DM, et al: Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. Int J Radiat Oncol Biol Phys 48:1035-1039, 2000
11. Bonner HS, Shaw LM: New dosing regimens for amifostine: A pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion. J Clin Pharmacol 42:166-174, 2002
12. Shaw LM, Bonner HS, Schuchter L, et al: Pharmacokinetics of amifostine: Effects of dose and method of administration. Semin Oncol 26:34-36, 1999 (suppl 7)
13. Koukourakis MI, Kyrias G, Kakolyris S, et al: Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study. J Clin Oncol 18:2226-2233, 2000
14. Anne PR, Curran WJ Jr: A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer. Semin Radiat Oncol 12:18-19, 2002 (suppl 1)